Corewell Health

Based in MI

🤖

AI Overview

With $3.6M in lobbying spend across 34 quarterly filings, Corewell Health is a significant lobbying presence. Their lobbying covers 7 issue areas. Active from 2018 to 2025.

$3.6M
Total Spend
8
Years Active
1
Firms Hired
4
Lobbyists Deployed
7
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2018$290K
2019$180K
2020$230K
2021$220K
2022$390K
2023$880K
2024$620K
2025$830K

Issues Lobbied

Lobbying Firms

Lobbyists

Government Agencies Targeted

These are the government entities that Corewell Health disclosed contacting in their lobbying filings.

HOUSE OF REPRESENTATIVESSENATECenters For Medicare and Medicaid Services (CMS)Health & Human Services, Dept of (HHS)Food & Drug Administration (FDA)Drug Enforcement Administration (DEA)Executive Office of the President (EOP)
View all agency pressure data →

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Medicare/Medicaid, Immigration, Labor Issues, Pharmacy and 2 more

H.R.1625 Consolidated Appropriations Act, 2018

H.R.2212 / S.974 Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2017: Discussions regarding proposed law to expedite generics

H.R.1625 Consolidated Appropriations Act, 2018

H.R.4392 Discussions regarding bill to reverse CMS final rule reducing payments for the 340B program.

H.R.908 Issues related to Medicare Advantage and th

H.R.4392 Discussions regarding bill to reverse CMS final rule reducing payments for the 340B program

H.R.908 Issues related to Medicare Advantage and the benchmark cap.

HR3325 & S.428: ACE Kids Act

HR908: Issues related to Medicare Advantage benefits and the benchmark cap.

Discussions regarding ACA Risk-Adjustment program

Related Analysis

Related Investigations

Similar Clients

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.